Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Trustees Report To Spark Renewed GOP Defense Of Reform Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

The federal government will start dipping into the Medicare trust fund nine years earlier than expected, moving the insolvency date up to 2019, trustees report. The Medicare reform law’s payments to health plans and rural providers contribute to the revised outlook.

You may also be interested in...

Medicare Rx Projections: CMS Says Average Per Capita Spending Will Grow 7.5% Per Year

Overall prescription drug spending growth will be 10% nationally, but Medicare Part D benefit will be able to keep costs to beneficiaries lower, Medicare trustees report says. CMS estimates size of drug benefit at $85 bil. in first year.

SEC Seeks Vaccine Manufacturer Input On Pediatric Stockpile Accounting

Securities & Exchange Commission regulations on revenue recognition are preventing childhood vaccine manufacturers from selling product to a government stockpile. Rep. Waxman declares support for a special exemption for vaccine makers.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts